TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23052809

Group type: EXPERIMENTAL
Intervention: Intravenous cefazolin 1 g
Number of subjects: 254

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study: 20642418

Group type: EXPERIMENTAL
Intervention: Group A: 3-monthly spirometry with regular medical review
Number of subjects: 305

Group type: COMPARATOR
Intervention: Group B: Spirometry only before and after the trial
Number of subjects: 305

Group type: COMPARATOR
Intervention: Group C: Usual care
Number of subjects: 305
Study: 18821166

Group type: EXPERIMENTAL
Intervention: Presenting unrelated semantic information during the fragment completion test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Activating both the solutions and blocking words for a particular fragment at study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Directed-forgetting instructions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 72-hour delay
Number of subjects: 0
Study: 15722804

Group type: EXPERIMENTAL
Intervention: Eccentric exercise
Number of subjects: 95
Study: 12061361

Group type: EXPERIMENTAL
Intervention: Bolus injection of indomethacin (n = 14)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Continuous infusion of indomethacin (n = 18)
Number of subjects: 32
Study: 10512905

Group type: EXPERIMENTAL
Intervention: Combined echoplanar MRI diffusion‐weighted imaging (DWI), perfusion imaging (PI), and magnetic resonance angiography (MRA)
Number of subjects: 34
Study: 7560032

Group type: EXPERIMENTAL
Intervention: Injured elbow (IE) radiographs
Number of subjects: 25

Group type: COMPARATOR
Intervention: Both injured and uninjured elbow (UE) radiographs
Number of subjects: 25
Study: 2110199

Group type: EXPERIMENTAL
Intervention: 0.2 mg per injection of IFN, subcutaneous injections three times weekly
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.02 mg of IFN, subcutaneous injections three times weekly
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo, subcutaneous injections three times weekly
Number of subjects: 45
Study: 6110582

Group type: EXPERIMENTAL
Intervention: Standard-dose oral contraceptives (50 microgram of estrogen)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Low-dose oral contraceptives (30 microgram of estrogen)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Both standard-dose and low-dose oral contraceptives
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Low-dose oral contraceptives
Number of subjects: 500
Study: 31904309

Group type: EXPERIMENTAL
Intervention: 250 mL distilled water with 10-minute rest in a supine position
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 250 mL distilled water with 30-minute rest in a supine position
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31422929

Group type: EXPERIMENTAL
Intervention: 3 months DAPT
Number of subjects: 1496

Group type: COMPARATOR
Intervention: 12 months DAPT
Number of subjects: 1496
Study: 27755225

Group type: EXPERIMENTAL
Intervention: Natural Restorative Environment (NRE) intervention
Number of subjects: 40

Group type: COMPARATOR
Intervention: Active control intervention
Number of subjects: 40
Study: 25733482

Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplement (LNS) fortified with multiple micronutrients (MMNs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: MMN supplement
Number of subjects: 0
Study: 24657484

Group type: EXPERIMENTAL
Intervention: TG4040 followed by PEG‐IFNα/RBV for 48 weeks with 6 injections of TG4040 (group C)
Number of subjects: 153

Group type: COMPARATOR
Intervention: PEG‐IFNα/RBV for 48 weeks (group A)
Number of subjects: 153

Group type: COMPARATOR
Intervention: PEG‐IFNα/RBV for 4 weeks followed by PEG‐IFNα/RBV for 44 weeks with 6 injections of TG4040 (group B)
Number of subjects: 153
Study: 22571226

Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg once daily for 3 days)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 19224888

Group type: EXPERIMENTAL
Intervention: SIMV plus pressure support
Number of subjects: 20

Group type: COMPARATOR
Intervention: SIMV alone
Number of subjects: 20
Study: 17473196

Group type: EXPERIMENTAL
Intervention: High trkC mRNA expression (>1x human cerebellum) and low c‐myc mRNA expression (<=1x human cerebellum)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: High c‐myc mRNA expression and low trkC mRNA expression
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Intermediate risk group (remaining 78 patients)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: High trkC mRNA expression in M(0) stage patients
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Low trkC mRNA expression levels in M(0) stage patients
Number of subjects: 133
Study: 10730025

Group type: EXPERIMENTAL
Intervention: Telephone reminder to the patient
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Telephone notification to the prescribing physician
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Postcard reminder to the patient
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Postcard notification to the prescribing physician
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study: 8959472

Group type: EXPERIMENTAL
Intervention: Lesopitron 20, 25, 30, 40, 45, 50, and 60 mg two times a day
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Lesopitron 60 mg two times a day
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Lesopitron (various doses)
Number of subjects: 42
Study: 1304766

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IGIV) 500 mg/kg
Number of subjects: 37

Group type: COMPARATOR
Intervention: Antibiotic treatment
Number of subjects: 37
Study: 3997971

Group type: EXPERIMENTAL
Intervention: Ambulated early (48 to 72 hours) with an immediate, post‐operative, pneumatic splinting device
Number of subjects: 80

Group type: COMPARATOR
Intervention: Did not ambulate early (NA)
Number of subjects: 80
Study: 30293831

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine infusion
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 90
Study: 30500140

Group type: EXPERIMENTAL
Intervention: Dapsone gel, 7.5%
Number of subjects: 2160
Study: 26539881

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy for Seasonal Affective Disorder (CBT-SAD)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Light Therapy
Number of subjects: 177
Study: 25274897

Group type: EXPERIMENTAL
Intervention: Naproxen (500 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 23106639

Group type: EXPERIMENTAL
Intervention: Acceptance
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Suppression
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control
Number of subjects: 162
Study: 18848786

Group type: EXPERIMENTAL
Intervention: Estramustine (E) 840 mg/day divided into three daily administrations on days 1-5 plus DOC 70 mg/m² on day 2
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Estramustine (E) plus DOC
Number of subjects: 25
Study: 18786729

Group type: EXPERIMENTAL
Intervention: ISST (International Suicide Prevention Trial Scale for Suicidal Thinking)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CDS (Calgary Depression Scale)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall characteristics of patients with Type 1 events
Number of subjects: 0
Study: 15800138

Group type: EXPERIMENTAL
Intervention: Donepezil treatment
Number of subjects: 147

Group type: COMPARATOR
Intervention: Control (no anti-Alzheimer drugs)
Number of subjects: 147
Study: 12847672

Group type: EXPERIMENTAL
Intervention: Early DMARD group
Number of subjects: 238

Group type: COMPARATOR
Intervention: Pyramid group
Number of subjects: 238
Study: 10235572

Group type: EXPERIMENTAL
Intervention: Stapled mesh
Number of subjects: 92

Group type: COMPARATOR
Intervention: Unstapled mesh
Number of subjects: 92
Study: 9036478

Group type: EXPERIMENTAL
Intervention: Rehabilitation programme (physical training, psychological action, control guidelines of risk factors)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 180
Study: 1886733

Group type: EXPERIMENTAL
Intervention: Continuous turning
Number of subjects: 17

Group type: COMPARATOR
Intervention: Intermittent turning
Number of subjects: 17
Study: 31982039

Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 222

Group type: COMPARATOR
Intervention: Best available therapy
Number of subjects: 222
Study: 28025868

Group type: EXPERIMENTAL
Intervention: Aquatic exercise
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cycling
Number of subjects: 10

Group type: COMPARATOR
Intervention: Walking
Number of subjects: 10
Study: 27537360

Group type: EXPERIMENTAL
Intervention: Blue LED light treatment (emission maximum: 453 nm), 3 times per week for 4 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Contralateral control lesion (untreated)
Number of subjects: 21
Study: 25047311

Group type: EXPERIMENTAL
Intervention: 1% feracrylum citrate solution
Number of subjects: 108

Group type: COMPARATOR
Intervention: Adrenaline (1:100,000)
Number of subjects: 108
Study: 23150980

Group type: EXPERIMENTAL
Intervention: Onsite heart failure service
Number of subjects: 28

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 28
Study: 20522353

Group type: EXPERIMENTAL
Intervention: Clinical and ultrasound assessment (Group B)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Clinical assessment alone (Group A)
Number of subjects: 50
Study: 17942609

Group type: EXPERIMENTAL
Intervention: Peptide-DC vaccine (3 million versus 10 million) administered intravenously or subcutaneously
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Peptide-DC vaccine
Number of subjects: 18
Study: 15696987

Group type: EXPERIMENTAL
Intervention: Blue light therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical 1% clindamycin solution
Number of subjects: 0
Study: 12858441

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Vitamin D3 and calcium supplementation alone
Number of subjects: 88
Study: 10805701

Group type: EXPERIMENTAL
Intervention: Light flashes (vision)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Finger vibrations (touch)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Vision (attending right vs. left)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Touch (attending right vs. left)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tactile stimuli with eyes open
Number of subjects: 12

Group type: COMPARATOR
Intervention: Tactile stimuli with eyes closed
Number of subjects: 12
Study: 8913976

Group type: EXPERIMENTAL
Intervention: 2.5 mg of PGE2 gel
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: 5.0 mg of PGE2 gel
Number of subjects: 119
Study: 1859518

Group type: EXPERIMENTAL
Intervention: CM 40907 (1200 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA, 1000 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CM 40907 (600 mg and 900 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CM 40907
Number of subjects: 12
Study: 6355052

Group type: EXPERIMENTAL
Intervention: Oral acyclovir treatment (200 mg, 5 times daily) for first episode HSV
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Oral acyclovir treatment for recurrent HSV
Number of subjects: 350

Group type: COMPARATOR
Intervention: Placebo for first episode HSV
Number of subjects: 350

Group type: COMPARATOR
Intervention: Placebo for recurrent HSV
Number of subjects: 350
Study: 30362105

Group type: EXPERIMENTAL
Intervention: MIL priming condition
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 68
Study: 31504594

Group type: EXPERIMENTAL
Intervention: Multi-enzyme complex
Number of subjects: 8

Group type: COMPARATOR
Intervention: Cornstarch-based diets with 31.3% CM
Number of subjects: 8
Study: 28669365

Group type: EXPERIMENTAL
Intervention: Psychogeriatric beds
Number of subjects: 0

Group type: COMPARATOR
Intervention: Somatic beds
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: National surveillance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Newly admitted dementia residents
Number of subjects: 0
Study: 27376047

Group type: EXPERIMENTAL
Intervention: Sulfamethoxazole‐trimethoprim (SMZ/TMP)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sulfamethoxazole‐trimethoprim (SMZ/TMP) plus ciprofloxacin
Number of subjects: 50
Study: 24332218

Group type: EXPERIMENTAL
Intervention: BI 671800 (200 mg twice daily)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg once daily)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate nasal spray (200 μg once daily)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: BI 671800 (all doses)
Number of subjects: 146
Study: 22134140

Group type: EXPERIMENTAL
Intervention: Guided self-help for SAD
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Unguided self-help for SAD
Number of subjects: 245
Study: 20465014

Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 480

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 480
Study: 16919758

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Sham EA
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (normal individuals)
Number of subjects: 90
Study: 15711245

Group type: EXPERIMENTAL
Intervention: Prostate surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronic urinary retention with large residual urine volumes (greater than 300 ml)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Detrusor instability and decreased bladder compliance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ureterovesicular junction obstruction from bladder remodeling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Episodic acute urinary retention, urinary tract infections, secondary hypertension
Number of subjects: 0
Study: 12193309

Group type: EXPERIMENTAL
Intervention: Single enema (400 mg of PTU in 90 mL of sterile water)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Two suppositories of polyethylene glycol base (200 mg of PTU in each)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both forms of PTU (enema and suppository)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both forms of PTU
Number of subjects: 15
Study: 9793286

Group type: EXPERIMENTAL
Intervention: Er:YAG laser preparation
Number of subjects: 103

Group type: COMPARATOR
Intervention: Conventional mechanical preparation
Number of subjects: 103

Group type: COMPARATOR
Intervention: Mechanical preparation
Number of subjects: 103
Study: 9097768

Group type: EXPERIMENTAL
Intervention: 0.5% apraclonidine
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: 1.0% apraclonidine
Number of subjects: 202
Study: 2523548

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1071693

Group type: EXPERIMENTAL
Intervention: Pharmacological therapy
Number of subjects: 81

Group type: COMPARATOR
Intervention: Low-sodium diet
Number of subjects: 81
Study: 31355898

Group type: EXPERIMENTAL
Intervention: Self-acupoint massage (SEAM) in addition to routine nursing interventions
Number of subjects: 66

Group type: COMPARATOR
Intervention: Routine nursing interventions
Number of subjects: 66
Study: 27431570

Group type: EXPERIMENTAL
Intervention: Kang'ai Xiaoshui ointment
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 26083953

Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccine
Number of subjects: 1660

Group type: COMPARATOR
Intervention: PNEUMOVAX 23 (active control)
Number of subjects: 1660
Study: 23870239

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol
Number of subjects: 82

Group type: COMPARATOR
Intervention: Lidocaine pump spray
Number of subjects: 82
Study: 20975521

Group type: EXPERIMENTAL
Intervention: Dominant hand training
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Nondominant hand training
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Overall training effect
Number of subjects: 200
Study: 19132414

Group type: EXPERIMENTAL
Intervention: Adper Prompt L-Pop
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two experimental formulations
Number of subjects: 0
Study: 16960176

Group type: EXPERIMENTAL
Intervention: Vitamin A and beta-carotene supplementation
Number of subjects: 225

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study: 15055228

Group type: EXPERIMENTAL
Intervention: Native lard (NL) diet for 28 days
Number of subjects: 4

Group type: COMPARATOR
Intervention: Randomized lard (RL) diet for 28 days
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 1,3‐tetradeuteriopalmitoyl‐2‐dideuteriolinoleoyl‐rac‐glycerol
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 1,3‐dideuteriolinoleoyl‐2‐tetradeuteriopalmitoyl‐rac‐glycerol and 1,3‐hexadeuteriopalmitoyl‐2‐tetradeuteriolinoleoyl‐rac‐glycerol
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 1‐acylphosphatidylcholine
Number of subjects: 4
Study: 11255136

Group type: EXPERIMENTAL
Intervention: Potassium phosphate supplementation (4,000 mg x day(-1) for 2 days)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 9875688

Group type: EXPERIMENTAL
Intervention: Grape procyanidin extracts (Leucoselect-phytosome) 300 mg, taken as two capsules daily for 5 days.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo, taken as two capsules daily for 5 days.
Number of subjects: 20
Study: 8090841

Group type: EXPERIMENTAL
Intervention: High-intensity electrical stimulation using console stimulators
Number of subjects: 110

Group type: COMPARATOR
Intervention: Low-intensity electrical stimulation using portable, battery-powered stimulators
Number of subjects: 110
Study: 2603606

Group type: EXPERIMENTAL
Intervention: Axillary dissection (Group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Axillary sampling (Group B)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Axillary dissection plus irradiation (Group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Other forms of treatment (Group B)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Axillary irradiation (Group A)
Number of subjects: 100
Study: 1096645

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: d-amphetamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31128926

Group type: EXPERIMENTAL
Intervention: Robot-assisted training
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: Enhanced upper limb therapy (EULT)
Number of subjects: 770

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 770

Group type: COMPARATOR
Intervention: Robot-assisted training vs Usual care
Number of subjects: 770

Group type: COMPARATOR
Intervention: EULT vs Usual care
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: Robot-assisted training vs EULT
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: EULT
Number of subjects: 770
Study: 27283343

Group type: EXPERIMENTAL
Intervention: Children's Health Activity Motor Program (CHAMP), 540 minutes, 9-week intervention
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (free-play, n=16)
Number of subjects: 38
Study: 25471305

Group type: EXPERIMENTAL
Intervention: Moderate energy-restricted diet for 10 weeks
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Baseline gene expression analysis
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Post-intervention gene expression analysis
Number of subjects: 12
Study: 22832202

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM)
Number of subjects: 96
Study: 21885257

Group type: EXPERIMENTAL
Intervention: Method 1 (previously developed to accurately identify Meyer's loop for planning anterior temporal lobe resection)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Method 2 (more automated technique to reduce operator time and depict the entire optic radiation)
Number of subjects: 10
Study: 18162423

Group type: EXPERIMENTAL
Intervention: Capsaicin (B1) followed by Glutamate (B2)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Glutamate (D1) followed by Capsaicin (D2)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Glutamate or Capsaicin injection
Number of subjects: 15

Group type: COMPARATOR
Intervention: Isotonic Saline (A1) followed by Glutamate (A2)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Isotonic Saline (C1) followed by Capsaicin (C2)
Number of subjects: 15
Study: 16579666

Group type: EXPERIMENTAL
Intervention: High-intensity functional weight-bearing exercise program
Number of subjects: 91
Study: 12665995

Group type: EXPERIMENTAL
Intervention: Low-molecular HES (6% HES 130/0.4) (n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Gelatin (n=20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 40
Study: 10555884

Group type: EXPERIMENTAL
Intervention: Alendronate (40 mg oral AL/day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 9038444

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tracheal tube
Number of subjects: 60

Group type: COMPARATOR
Intervention: Facemask
Number of subjects: 60
Study: 1974748

Group type: EXPERIMENTAL
Intervention: Beta‐adrenoceptor blocking agents (treated group, n = 39)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Isoflurane anesthesia (0.5%‐0.6% end‐tidal) plus 50% nitrous oxide
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (n = 22, no preoperative beta-blocker therapy)
Number of subjects: 61
Study: 6454387

Group type: EXPERIMENTAL
Intervention: Moxalactam
Number of subjects: 21

Group type: COMPARATOR
Intervention: Cefazolin
Number of subjects: 21
Study: 31785551

Group type: EXPERIMENTAL
Intervention: Self-reported poorly controlled hypertension
Number of subjects: 0
Study: 30829120

Group type: EXPERIMENTAL
Intervention: HIV self‐testing (HIVST)
Number of subjects: 40

Group type: COMPARATOR
Intervention: HIV counselling and testing (HCT)
Number of subjects: 40
Study: 27876460

Group type: EXPERIMENTAL
Intervention: IMO-8400
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46